Dr. Henry S. Park is a board-certified radiation oncologist who currently serves as Assistant Professor of Therapeutic Radiology and as the Director of Thoracic Radiotherapy at the Yale School of Medicine. He received his undergraduate degree from Yale College, master's degree from the Harvard School of Public Health, and medical doctorate degree from the Yale School of Medicine. He completed his internal medicine internship at Harvard Medical School's Beth Israel Deaconess Medical Center and returned to Yale New Haven Hospital for his residency and chief residency in radiation oncology. Dr. Park is an active comparative effectiveness, health services researcher, and clinical trialist, having co-authored over 130 peer-reviewed original research articles, reviews, and chapters. He is particularly interested in improving patient access to high-quality oncologic care, especially for patients with lung cancer. He also serves as the department's director of continuing medical education, director of medical student education, and associate program director of the residency.

Paul K. Paik, MD is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in the treatment of lung cancers.  He is an Associate Attending Physician in the Thoracic Oncology Service at MSKCC, an Associate Professor of Medicine at Weill Cornell Medical College, and serves as the Clinical Director for the Thoracic Oncology Program at MSKCC.  Dr. Paik’s research focuses on squamous cell lung cancer, targeted therapeutics, and translational therapies aimed at the metastatic process.

Sukhmani (Suki) Padda MD is an Assistant Professor of Medicine in the Department of Medicine, Division of Oncology at Stanford University. She is a thoracic medical oncologist, with a specific clinical and research focus in EGFR and KRAS mutated NSCLC, lung neuroendocrine tumors, and thymic malignancies. She graduated from 6-year medical program Northeast Ohio Medical University. She has been involved in clinical research in thoracic oncology since graduating medical school. She completed her internal medicine residency and hematology/oncology fellowship at Stanford University.

Assistant Professor in Thoracic Oncology and Developmental Therapeutics at the University of Colorado Anschutz Cancer Center. Interests include clinical trial design, teaming with translational scientists and education. Has participated as a local principal investigator on cooperative group studies, studies involving agents targeting the RAS pathway (SHP2 inhibitors, KRAS G12C inhibitors), and antibody drug conjugates. Has published approximately 40 peer reviewed articles to date. Hobbies include hiking and fitness.

Dr. Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University. He is also a Georgia Research Alliance Distinguished Cancer Scientist. He received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000. He was a postdoctoral research fellow at the Johns Hopkins University in Baltimore, USA from 2000 to 2002. He completed Internal Medicine residency training at the Graduate Hospital, Drexel University in Philadelphia in 2005 followed by a clinical fellowship in Hematology/Medical Oncology at the University of Pittsburgh in 2008. He has been on faculty at Emory University since 2008 and has focused his translational research activities on lung cancer, thyroid cancer and early phase drug development. Dr. Owonikoko has received peer-reviewed grant funding from the NIH, DOD and Georgia Cancer Coalition. He has published over 227 peer-reviewed manuscripts in high impact journals including New England Journal of Medicine, Cell, Science, Nature, CA Cancer Journal, Cancer Cell, Lancet Oncology, JCO, Cancer Discovery, Nature Communications, Oncogene, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.

Dr. Owen is a clinical investigator focusing on novel therapeutic interventions for patients with thoracic malignancies. Dr. Owen designed and opened several early phase clinical trials as investigator-initiated studies, ranging from single-site phase I studies to national NCI-CTEP phase I/II trials. Dr. Owen has been collaborating with translational research teams to develop and conduct a phase I study in patients with NSCLC targeting the adenosine pathway with an oral immunotherapy titled “PBF-1129 in patients with advanced Non-Small Cell Lung Cancer (NSCLC)” (NCT03274479). Dr. Owen has worked to better understand the unique toxicities that occur in patients treated with immunotherapies and strategies to predict and mitigate these toxicities.

Health Science Clinical Professor at University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center at Orange, California, USA. Associate Editor at JTO and JTO-CRR. Clinical interests in phase 1 targeted therapy trials, molecular epidemiology of RTK-fusions and ligand fusions, and overcoming resistances to targeted therapy.

I've been at OSU/James for 20 years, previously having done my fellowship at NCI. Currently focused on translational therapeutics.

Dr. Osarogiagbon currently serves as Director of the Multidisciplinary Thoracic Oncology Program at the Baptist Cancer Center, in Memphis, Tennessee. He also serves as Director of the Thoracic Oncology Research (ThOR) Group of the Baptist Cancer Center and is the Principal Investigator of three ongoing National Institutes of Health-funded research projects, as well as IH-1304-6147, a recently completed  Patient Centered Outcomes Research Institute-funded comparative effectiveness study of multidisciplinary v serial care for lung cancer titled ‘Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology.’ Dr. Osarogiagbon’s research interests center around improving population-level outcomes of cancer care by improving systems of care-delivery, improving the accuracy of cancer staging and evaluating the biologic drivers of outcome differences in potentially curable lung cancer. He is a member of the Cancer Prevention Steering Committee of the National Cancer Institute and a member of the Staging and Prognostic Factors and the Strategic Planning Committees of the International Association for the Study of Lung Cancer.

Dr. Joel Neal, MD, PhD, is Associate Professor of Medicine (Oncology) at the Stanford Cancer Institute in Palo Alto, California, United States. He maintains an active thoracic medical oncology practice, and also directs the Stanford Thoracic Clinical Research Group which focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer, mesothelioma, and other thoracic malignancies. He participates in the IASLC Continuing Medical Education Committee, and as an active member of the ECOG-ACRIN national cooperative group, he has chaired multiple lung cancer studies. He also serves as IT medical director of Stanford Cancer Center.